EMEA (Europe, Middle East and Africa) Substance Abuse Treatment Market - Segmented by Abuse type, Treatment, End-User and Geography - Growth, Trend and Geography (2018 - 2023)

  • ID: 4472696
  • Report
  • Region: Africa, EMEA, Europe, Middle East
  • 99 pages
  • Mordor Intelligence
1 of 4


  • Alkermes plc
  • Allergan
  • GSK
  • Mallinckrodt
  • Mylan Laboratories
  • Pfizer
  • MORE
The EMEA substance abuse treatment market is expected to register a CAGR of approximately 9.0% during the forecast period, 2018 to 2023. Europe accounts for the larger market share than Middle-East and Africa primarily due to the favorable regulatory framework by the government in that region.

Rising Drug Awareness Campaigns and Prevention Programs

The rise in the drug awareness campaigns and associated prevention programs is one of the primary factors linked to the growth of substance abuse treatment market in EMEA region. It includes rising patient awareness, higher treatment seeking rate with increased government intervention and encouragement to curb substance abuse in several countries helps in the growth of the market. Medications which help avoid relapse and control drug cravings also propels this market. Apart from that, increasing number of treatment centers are entering the market which has collaborations with private recovery facilities which helps in expansion of the treatment access to larger number of people in the society.

Furthermore, other factors such as such as high number of addicted population and technological advancement in the diagnostics industry is transforming and driving this market.

Discontinuation of the Behavioral Therapies

The discontinuation of the behavioral therapies often leads to relapse of addiction, which is crucial factor hindering the growth of this market. Many patients opt for outpatient care for treatment of drug dependence but for many this outpatient treatment is highly challenging which makes addicts unable to or unwilling to adhere to program requirements which as a result leads to repeated admissions and drop outs. Apart from that, there is high reluctance of individuals in accessing treatment modalities and poor treatment compliance in some countries hinders the growth of this market.

Europe to Dominate the Treatment by Nicotine Gum

The EMEA substance abuse treatment market has been segmented by abuse type, treatment, end-user and geography. By treatment, the market has been further segmented by alcohol addiction, tobacco/nicotine addiction and drug abuse. By Geography, two global regions Europe and Middle-East and Africa has been further segmented into country wise division.

Europe has one of the highest prevalence of tobacco smoking consumptions among adults with approximately 30% and one of the highest prevalence of tobacco use by adolescents. The gap of prevalence between male and female adults is less than 5% in countries such as Denmark, Ireland, the Netherlands, Norway, Sweden and the UK. OTC products such as Nicotine chewing gums are widely consumed and available across Europe because of their safety and fewer side effects which drives this market in this region.



To know more about:
  • Market analysis for the EMEA Substance Abuse Treatment Market, with region-specific assessments and competition analysis on a global and regional scale.
  • Analyzing various perspectives of the industry with the help of Porter’s five forces analysis
  • The treatment type that is expected to dominate the market
  • Regions that are expected to witness fastest growth during the forecast period
  • Identify the latest developments, market shares and strategies employed by the major market players.
  • 3 months analyst support along with the Market Estimate sheet in excel.
This report can be customized to meet your requirements. Please contact us for more information.
Note: Product cover images may vary from those shown
2 of 4


  • Alkermes plc
  • Allergan
  • GSK
  • Mallinckrodt
  • Mylan Laboratories
  • Pfizer
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rising Drug Awareness Campaigns and Prevention Programs
6.1.2 High Number of Addicted Population
6.1.3 Technological Advancement in the Diagnostics Industry
6.2 Market Restraints
6.2.1 Reluctance of Individuals in Accessing Treatment and Discontinuation Of The Behavioral Therapies
6.2.2 Poor Treatment Compliance in Some Countries
6.3 Market Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Abuse Type
7.1.1 Alcohol Dependence
7.1.2 Tobacco/Nicotine Addiction
7.1.3 Opioid Addiction
7.1.4 Others
7.2 By Treatment
7.2.1 Alcohol Addiction Treatment Disulfiram Acamprosate Naltrexone Others
7.2.2 Tobacco/Nicotine Addiction Treatment Nicotine Replacement Treatment Nicotine Patch Nicotine Gum Nicotine Lozenge Nicotine Spray Nicotine Inhaler Non-Nicotine Medication Bupropion Varenicline Others Others
7.2.3 Drug Abuse Treatment Methadone Buprenorphine Others
7.3 By End-User
7.3.1 Outpatient Treatment Centers
7.3.2 Residential Treatment Centers
7.3.3 Inpatient Treatment Centers
7.4 Segmentation, By Geography
7.4.1 Europe France Germany United Kingdom Italy Spain Rest of Europe
7.4.2 Middle East & Africa GCC South Africa Rest of Middle East & Africa

8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches

9. Key Players
9.1 Allergan
9.2 Sanofi Aventis S.A
9.3 GSK
9.4 Pfizer
9.5 Alkermes Plc.
9.6 Mylan Laboratories
9.7 Purdue Pharma Lp
9.8 Reckitt Benckiser Pharmaceuticals
9.9 Teva Pharmaceuticals
9.10 Mallinckrodt
9.11 Others

10. Future of the Market
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Allergan
  • Sanofi Aventis sa
  • GSK
  • Pfizer
  • Alkermes plc
  • Mylan Laboratories
  • Purdue Pharma lp
  • Reckitt Benckiser Pharmaceuticals
  • Teva Pharmaceuticals
  • Mallinckrodt
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown